×

RNS Number : 9074O

React Group PLC

22 May 2018

 

22 May 2018 

                                                              REACT Group plc

                                                  (the ''Company'' or ''React'')

Additional contract with major highways construction company

REACT is pleased to announce that it has signed an additional service contract with a major Highway's Construction Company for the provision of decontamination and deep cleaning services, for Picnic and Amenity sites and various service depots running from Dorset through Devon and Cornwall.  This is a 12 month rolling contract totalling £225,000. 

For further information please contact:  

REACT Group PLC

Gill Leates: Chairman                                                                                                   07799 662642

 

SPARK Advisory Partners Limited (NOMAD)                                                            0113 370 8974

Neil Baldwin

 

Whitman Howard Limited (Broker)

Nick Lovering                                                                                                                 0207 659 1224

 

Peterhouse Corporate Finance Limited (Broker)                                                      

Duncan Vasey / Martin Lampshire                                                                            0207 459 0930

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

NRALLFVFESIFFIT

Close

×

RNS Number : 6516O

Midatech Pharma PLC

21 May 2018

 

21 May 2018

Midatech Pharma PLC

("Midatech", "Company" or "Group")

 

Midatech commences equivalence study in exploratory phase of Q-Octreotide (MTD201) for carcinoid cancer and acromegaly

 

–      Initial dosing administered in potentially pivotal phase for core near-to-market oncology asset

 

Midatech (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused on developing and commercialising products in oncology and immunotherapy, today announces that it has commenced initial dosing in the first in-human study of the Company's sustained release product Q-Octreotide (MTD201) for the treatment of carcinoid cancer and acromegaly, two rare and debilitating hormone-based tumours with high mortality and morbidity rates.

 

The clinical equivalence study is being conducted in 24 healthy subjects in a double-blind, randomised, parallel group protocol to evaluate the interchangeability between Q-Octreotide and the reference product, Sandostatin® LAR® ("SLAR"), following single dose administration. The aim is to establish equivalence of Q-Octreotide with SLAR, and to show that it can achieve safe and effective growth hormone levels in patients. The Company expects data for this study to be available in the second half of 2018 and intends to expand the study into a pivotal registration study, of similar design in up to 100 subjects, to complete in the first half of 2019.

 

The Company is seeking the same marketing product label indications as SLAR. Moreover, the Company plans to highlight the potential advantages of Q-Octreotide with prescribers and regulators. These advantages, made possible by Midatech's novel sustained release microsphere (Q-Sphera) technology, include: improved speed and simplicity of reconstitution along with fewer errors, a less painful injection with fewer blockages, minimal wastage with fewer repeat injections and errors, and improved economics.

 

Pending positive clinical data showing equivalence and completion of commercial scale manufacture requirements, the Company expects to file for marketing authorisation with the U.S. Food and Drug Administration (FDA) in 2020. The Company believes Q-Octreotide could capture up to 5% of the $2 billion annual market for SLAR1.

 

Midatech's CEO-designate, Dr Craig Cook, commented: "We are pleased to initiate this key study for one of our core programmes in oncology, MTD201, which also represents an important milestone for our sustained release Q-Sphera technology and its potential use in future products. Having resolved important manufacturing challenges and requirements, and incorporated invaluable regulatory authority feedback into the program design, we are confident that we have a robust study which will provide meaningful data on MTD201 in the second half of this year. Our pre-clinical data so far illustrates the interchangeability as well as numerous benefits of Q-Octreotide as a therapy for the debilitating and lethal diseases of carcinoid cancer and acromegaly versus the standard of care. We are working hard to bring this product to market to offer patients, physicians and payors an alternative choice for treating these diseases."

 

1 www.novartis.com; www.ipsen.com

 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014 (MAR).

 

– Ends –

 

For more information, please contact:

 

Midatech Pharma PLC

Craig Cook, CEO-designate

Nick Robbins-Cherry, CFO

Tel: +44 (0)1235 888 300

www.midatechpharma.com

 

Panmure Gordon (UK) Limited (Nominated Adviser and Broker)

Freddy Crossley / Emma Earl / Ryan McCarthy

Tel: +44 (0)20 7886 2500

 

Consilium Strategic Communications (Financial PR)

Mary Jane Elliott / Ivar Milligan / Nicholas Brown

Tel: +44 (0)20 3709 5700

Email: [email protected]

 

Westwicke Partners (US Investor Relations)

Chris Brinzey

Tel: +1 339 970 2843

Email: [email protected]

 

 

Notes for Editors

 

About Midatech Pharma PLC

Midatech is an international specialty pharmaceutical company focused on the research and development of a pipeline of medicines for oncology and immunotherapy. Midatech's strategy is to internally develop oncology products, and to drive growth both organically and through strategic acquisitions. The Company's R&D activities are focused on three innovative platform technologies to deliver drugs at the "right time, right place": gold nanoparticles ("GNPs") to enable targeted delivery; Q-Sphera polymer microspheres to enable sustained release ("SR") delivery; and Nano Inclusion ("NI") to provide local delivery of therapeutics, initially to the brain. Midatech Pharma US is the Group's US commercial operation, with four cancer supportive care products and two further co-promoted products. The Group, listed on AIM: MTPH and Nasdaq: MTP, employs c.100 staff in four countries. For further company information see: www.midatechpharma.com

About carcinoid cancer and acromegaly

Carcinoid cancer is a cancer of the neuroendocrine system in which tumours can grow in various regions of the body. Around 15,000 people are diagnosed with carcinoid tumours every year in the UK and the US.2 3 Acromegaly is an endocrine system disorder which develops when the pituitary gland produces excessive amounts of growth hormone. Around 4 people per million are diagnosed with acromegaly annually.4 Both conditions are rare and have high mortality and morbidity rates.

 

2 www.cancerresearchuk.org

3 www.cancer.net

4 www.pmj.bmj.com

 

Forward-Looking Statements

Certain statements in this press release may constitute "forward-looking statements" within the meaning of legislation in the United Kingdom and/or United States. Such forward-looking statements include, but are not limited to, statements regarding the ability of Midatech to successfully test, manufacture, produce or commercialize products for conditions using the nanoparticle and sustained release drug delivery platforms, and the ability for products in development to achieve positive clinical results, and the ability to meet or achieve timelines associated with pre-clinical studies, clinical trials or regulatory submissions. Any forward-looking statements are based on currently available competitive, financial and economic data together with management's views and assumptions regarding future events and business performance as of the time the statements are made and are subject to risks and uncertainties. We wish to caution you that there are some known and unknown factors that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements.

 

Reference should be made to those documents that Midatech shall file from time to time or announcements that may be made by Midatech in accordance with the London Stock Exchange AIM Rules for Companies ("AIM Rules"), the Disclosure and Transparency Rules ("DTRs") and the rules and regulations promulgated by the US Securities and Exchange Commission, which contains and identifies other important factors that could cause actual results to differ materially from those contained in any projections or forward-looking statements. These forward-looking statements speak only as of the date of this announcement. All subsequent written and oral forward-looking statements by or concerning Midatech are expressly qualified in their entirety by the cautionary statements above. Except as may be required under the AIM Rules or the DTRs or by relevant law in the United Kingdom or the United States, Midatech does not undertake any obligation to publicly update or revise any forward-looking statements because of new information, future events or otherwise arising.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

MSCLBLLLVEFFBBV

Close

×

RNS Number : 4127N

Microsaic Systems plc

09 May 2018

 

9 May 2018

Microsaic Systems plc

 

("Microsaic"or the "Company")

 

Agreement with Rightek Co., Ltd.

 

Microsaic Systems plc (AIM: MSYS), the developer of point of need mass spectrometry ("MS") instruments, is pleased to announce that it has signed an agreement with Rightek Co., Ltd. ("Rightek") (the "Agreement").

 

The Agreement covers the distribution of Microsaic's 4500 MiD® mass spectrometry detector via Rightek's distribution network in Taiwan.

 

Glenn Tracey, CEO of Microsaic, commented, "This agreement with Rightek further consolidates our strategy to extend the sales of our unique compact, point of need technology into the Asia Pacific area.

 

Rightek combines expertise in understanding end-user applications, together with a proven track record of working with a wide range of specialised scientific instrumentation.

 

This agreement is in line with our strategy to partner with locally based and established channel partners, with expertise in selling innovative analytical instrumentation to progressive end-users in process and pharmaceutical markets."

 

Moses Shih, General Manager of Rightek, added "Rightek is committed to helping our customers achieve success, to solve their problems by finding suitable high-quality technologies to meet ever challenging demands. We believe that Microsaic's compact, point-of-need systems can improve the efficiencies by optimizing the process in chemical and pharma industries."

Enquiries:
Microsaic Systems plc Glenn Tracey, CEO Bevan Metcalf, FD	+44 (0) 1483 751577
N+1 Singer (Nominated Adviser & Broker) Shaun Dobson Liz Yong	+44 (0)20 7496 3000
IFC Advisory Ltd (Financial PR) Graham Herring Heather Armstrong Florence Chandler	+44 (0)20 3934 6630

 

 

About Microsaic Systems

Microsaic Systems plc (AIM: MSYS) is a high technology company developing chip-based, bench-top and point-of-analysis mass spectrometry ("MS") instruments that are designed to improve the efficiency of pharmaceutical R&D and manufacturing. The Company is working with established global life science companies to co-develop new solutions to improve productivity in the development of small molecule and novel biologic (peptides, antibodies) medicines. MS is a powerful method of analysis to enable earlier decision making relating to product identification, purity and bioactivity, and is the analytical technique of choice for biochemists across many industry sectors.

 

Microsaic's core product, the 4500 MiD®, is a robust and compact MS system, retaining the functionality of larger conventional MS systems, is easier to use by non-specialists, consumes less energy and has lower running costs. For more information, please go to www.microsaic.com.  

 

 

About Rightek Co., Ltd

Established in December 2007, Rightek is headquartered in Wujin District, New Taipei City, and also has offices in Taichung and Kaohsiung. Rightek distributes a wide range of scientific equipment through its Analytical, Synthesis and Process Equipment divisions.

 

 

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

AGREASSPELEPEFF

Close

×

RNS Number : 5452N

EU Supply PLC

09 May 2018

 

RNS Reach

9 May 2018

EU Supply plc

("EU Supply", the "Company" or the "Group")

 

Contract Win

 

EU Supply (LSE AIM: EUSP), the e-procurement software provider, is pleased to announce that the Group has signed a contract with "Welthungerhilfe", a German private aid organisation. The contract is for delivery of CTMTM as SaaS and related services and is expected to generate, in aggregate, sales of €55k over a three year period.

 

 

FURTHER ENQUIRIES

EU Supply PLC Tel: 020 7127 4545 Thomas Beergrehn, CEO   Fredrik Wallmark, CFO       Stockdale Securities Tel: 020 7601 6100 Tom Griffiths, Ed Thomas

 

A copy of this announcement is available at www.eu-supply.com.

 

Notes to Editors

EU Supply is the UK holding company of the EU Supply Group, a Sweden-based e-commerce business, which has an established, market-leading, multilingual e-procurement platform for esourcing, e-tendering and contract management, tailored for the highly regulated European public sector market.

Since 2006, the Group has invested heavily in employing specialist programmers to add functionality, legal compliance as required and security features to its Complete Tender Management™ ("CTM™") platform to ensure that the Group is ideally placed to secure new contracts with EU Member States and their Contracting Authorities. The platform is available in 16 different languages.

The Directors believe that the Group's CTM™ platform is one of the easiest to use and most functionally advanced solutions available in the market. The CTM™ platform is used by over 8,000 European public sector bodies in 9 EU/EEC Member States and has National Procurement System status in four Member States (the UK, Ireland, Norway and Lithuania).

The Company's shares were admitted to trading on AIM in November 2013. In August and September 2015, the Company raised a total of £2.061m (before expenses) through a placing of new shares and the issue of first and second tranches of Convertible Loan Notes to institutional and other investors.

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

NRAXKLFBVEFLBBK

Close

×

RNS Number : 2606N

Transense Technologies PLC

08 May 2018

 

Transense Technologies plc

("Transense" or the "Company")

New Translogik iTrack Contract Win in new Territory

 

Transense Technologies plc, the provider of sensor systems for the transportation and industrial markets, is pleased to announce that Translogik, its trading division providing tyre management solutions, has won a contract through its Ghanaian partner WATS (West African Tyre Services) to supply 16 iTrack II mining tyre monitoring systems for large haul trucks at SOMITA, a Nordgold mine in Burkina Faso.

These systems are to be supplied on a rental and service basis via WATS, which is a wholly owned subsidiary of Rana Motors & Metal Works Engineering Company Ltd. This method allows mining companies to benefit from the productivity gains and overhead savings provided by using the system without any of the associated capital cost while providing Translogik with a recurring revenue stream.

Vibi Chandra, Director, Sales & Services Director, OTR Tyres, WATS, said: "Having conducted extensive trials over the course of the last 18 months we have chosen iTrack because its combination of live alerts and extensive suite of data analytics is crucial to enhancing our offering as Tyre Service Providers. West Africa is a region with dozens of mines and hundreds of haul trucks and it is our intention to introduce our new enhanced service to our existing portfolio of mines as well as other mines across the region. We know these mines are very interested in the significant advantages we are now able to offer and we fully expect further advances and new contracts in the future."

 

Graham Storey, CEO of Transense, said: "We are very pleased to have added another mine in a new region to our growing list of iTrack users. WATS are a well established and highly regarded Tyre Service Provider in West Africa and with their depth of contacts we are hopeful of an accelerated rate of adoption as we move forward."

 

For further information, please visit www.transense.co.uk or contact:

 

Transense Technologies plc Graham Storey, Chief Executive	Tel: +44 1869 238 380
finnCap (Nomad and Broker) Ed Frisby, Giles Rolls (Corporate Finance) Abigail Wayne, Camille Gochez (Corporate Broking)	Tel: +44 20 7220 0500

  

Notes to editors:

About iTrack II

The iTrack II Mining system provides fast, accurate, reliable real-time data on the condition of the tyres, combined with live tracking of vehicle location and status. Our 24/7 Control Room monitors the  pressures and temperatures live, and this information can, for example, be used to ensure tyres do not exceed critical heat thresholds, detect incorrect load distributions, predict suspension failures, eliminate manual tyre pressure checks and much more. All of these benefits increase health and safety as well as reducing maintenance and downtime, which maximises the hours a truck is working (On-Road Truck Working Hours), which directly correlates to an increase in production.

Existing iTrack users have reported increases in tyre life of up to 30% and fuel savings of up to 3%. Savings of this magnitude provide a rapid return on investment with the iTrack system paying for itself in a matter of months and where the rental option is chosen the system will pay for itself from day one.

www.trans-logik.com/itrack-2/

 

About WATS

WATS is a leading provider of earthmover/off-the-road tyre management services to the mining industry. Their credentials are based on a proven ability to reduce the cost of earthmover tyre operation for major open-pit miners while maximising production and enhancing safety. Advanced engineering systems and innovative maintenance, analysis and reporting technologies combine to consistently reduce client tyre costs, typically by 20% or more. As an independent technical adviser and service provider to mining companies in West Africa WATS has established an impressive track record.

 

http://www.watsltd.com/

 

The information communicated in this announcement is inside information for the purposes of Article 7 of Regulation 596/2014.

 

 

 

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

CNTFKODQPBKDBPK

Close

×

RNS Number : 8009M

Nanoco Group PLC

02 May 2018

 

NANOCO GROUP PLC

("Nanoco" or the "Group")

 

Nanoco Group PLC launches new business, Nanoco 2D Materials Ltd

 

Nanoco 2D Materials Ltd raises seed funding and announces collaboration with The University of Manchester and Nobel Laureate, Professor Konstantin Novoselov

 

Nanoco Group plc (LSE: NANO), a world leader in the development and manufacture of cadmium-free quantum dots and nano-materials, announces the launch of Nanoco 2D Materials Ltd "2D Materials", a wholly owned subsidiary focused on the development and commercialisation of a new generation of nano-materials.

Two dimensional nano-particles are a platform technology which are one or two atoms thick and a few nanometres wide and represent a burgeoning field of material science.  Currently there is no cost-effective way to produce these 2D materials on a commercial scale nor any reliable method to ensure consistent properties suitable for the wide range of potential electronics, industrial and other applications. 

For the past year Nanoco has been collaborating with Professor Novoselov, 2010 winner of the Nobel Prize for Physics for his work on graphene, with the goal to establish feasibility for these exciting new materials.  Based on the positive results seen to date, 2D Materials has been created to formalise the partnership between the two groups, ensure funding is in place and continue the development of the technology.

The £400,000 funding comes from The University of Manchester in the form of a 10-year convertible loan note which carries a 6.5% coupon.

Dr Nigel Pickett, CTO and co-founder of Nanoco, said:

"By combining Nanoco's expertise with the knowledge base from Professor Novoselov's lab we have been able to push the boundaries of material science to come up with a new generation of versatile 2D nano-particles and are now utilising Nanoco's 15 years of scale-up expertise on methods to produce them at commercial scale.  Potential commercial applications for these materials span across a wide range of sectors including novel catalysts, photo-detectors, photovoltaics, inverters and light emitting devices."

Professor Novoselov added:

"It is exciting to see how quickly 2D materials, beyond graphene, has accelerated from the early research stage to the technology we now have. Working with a very knowledgeable and dedicated Nanoco team continues to be a very refreshing experience. The ability of our combined teams to focus on particular technological and performance parameters is allowing the rapid development of these 2D Materials."

 Clive Rowland, CEO of the University's innovation company UMI3, commented:

"Part of the University's strategy for commercialising graphene and its sister 2D materials is to work with existing companies and entrepreneurs to help them set-up R&D centres and new companies close to the campus to create a technology innovation ecosystem here – Graphene City®. I'm delighted that we are working with Nanoco, which itself is a spin-out from the University. Its experience in the handling and scaling up of nanomaterials and access to its relevant facilities were key factors in us deciding to support this initiative."

About the convertible note:

The £400,000 funding comes from The University of Manchester in the form of a 10-year convertible loan note which carries a 6.5% coupon. Interest payments are accrued until conversion or repayment of the loan takes place.  The loan note is convertible into new shares of 2D Materials and any conversion event is dependent on an additional £1m of third party investment into 2D Materials or sale or flotation of 2D Materials.

 

 

For further information, please contact:

 

Nanoco	Tel: +44 (0) 161 6037900
Michael Edelman, Chief Executive Officer
David Blain, Chief Financial Officer
Caroline Watson, Investor Relations Manager	Tel: + 44 (0) 7799 897357
[email protected]
Peel Hunt	Tel: +44 (0) 20 7418 8900
Adrian Trimmings
George Sellar
MHP Communications	Tel: +44 (0) 20 3128 8788
Reg Hoare / Giles Robinson / Pete Lambie [email protected]

 

 

Notes for editors:

 

About Nanoco Group plc

Nanoco (LSE: NANO) harnesses the power of nano-technology to create a brighter, more sustainable future. Based on breakthrough science, Nanoco's proprietary manufacturing process enables the large-scale production of its cadmium-free CFQD® quantum dots for multiple applications including LCD display, lighting, healthcare, nano-materials and solar.

 

Nanoco has non-exclusive manufacturing and marketing licensing agreements in display with The Dow Chemical Company, Merck KGaA of Germany and Wah Hong Industrial Corporation of Taiwan.

 

Nanoco was founded in 2001 and is headquartered in Manchester, UK, with a US subsidiary, Nanoco Inc., in Concord, MA. Nanoco continues to build out a world-class, patent-protected IP portfolio generated both by its own innovation engine, as well as through acquisition. 

 

About UMI3

The University of Manchester I3 Ltd (www.umi3.com) is The University of Manchester's agent for intellectual property commercialisation. UMI3 is wholly owned by the University which has over a 30 year history of IP commercialisation.

UMI3's role is to bring as much of the University's ground-breaking inventions and software, as is relevant, into the commercial world. This we do principally by attracting entrepreneurs, investors and corporate venture partners to our campus and Innovation Centre (www.umic.co.uk) and then, through engagement with our academic colleagues, licensing or spinning out companies.

Since 2004 over 4,000 invention disclosures have been received. UMI3 has set up 41 spin-out companies and 51 social enterprise spin-outs, staff start-ups and assisted student start-ups. Over 7,500 licences and assignments have been brokered and over £360M has been invested by 3rd party venture funders in University of Manchester spin-outs, a number of which have received national and regional enterprise awards. It currently has over 100 projects in its portfolio at various stages of development.

 

The University's IP enterprises have generated over £115M to the University through the sale of shares in spin-outs, licensing income and through IP grants and contracts activity.

For more information, please visit www.umip.com

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

UPDEASSFELDPEFF

Close

×

RNS Number : 8419L

Warpaint London PLC

24 April 2018

 

24 April 2018

Warpaint London plc

("Warpaint London" or the "Company")

Queen's Award for International Trade  

 

Warpaint London plc (AIM: W7L), the specialist supplier of colour cosmetics and owner of the W7 and Technic brands, is pleased to announce that Warpaint Cosmetics (2014) Ltd, a trading subsidiary of the Company, has been awarded the Queen's Award for International Trade for outstanding growth in overseas sales over the last three years.

The Queen's Awards for Enterprise recognises outstanding achievement by UK businesses in the categories of Innovation, International Trade and Sustainable Development. The awards are presented annually by HM The Queen, and are given for the highest levels of excellence demonstrated by a UK based company. The Queen's Award for International Trade recognises businesses that have achieved substantial growth in overseas earnings and in commercial success.

The Company has seen overseas sales increase steeply between 2014 and 2016 from £2.0 million to £10.4 million. Total growth in revenue over the period was 420% and overseas sales as a percentage of total sales rose year on year.

Commenting, Sam Bazini and Eoin Macleod, Joint Chief Executives of Warpaint, said: "We are extremely honoured and proud to be selected for a Queen's Award, and we would like to take this opportuntity to recognise the hard work and dedication of our employees, and efforts of our partners and distributors globally.

"To receive one of the most prestigious and internationally recognised awards for our international trade efforts reflects our strategy to continually progress as a business and drive the success of our brands, both domestically and overseas."

Enquiries:

Warpaint London PLC     Sam Bazini – Joint Chief Executive Officer Eoin Macleod – Joint Chief Executive Officer Neil Rodol – Chief Financial Officer	c/o IFC
Stockdale Securities Limited (Nominated Adviser and Broker) Antonio Bossi, Ed Thomas – Corporate Finance Fiona Conroy – Corporate Broking	020 7601 6100
IFC Advisory Limited (Financial PR & IR) Tim Metcalfe Heather Armstrong Florence Chandler	020 3934 6630

 

 

 

 

About Warpaint London plc

Warpaint London is a colour cosmetics business, based in Iver, Buckinghamshire. It is made up of two divisions: close-out and own-brand.  The second and larger own-brand division consists primarily of the Group's flagship brand, W7 – an extremely creative, design-focused cosmetic brand proposition with a focus on the 16-30 age range, delivering high-quality cosmetics at affordable prices. The W7 brand has grown organically since its inception in 2002 and now contains over 500 items which are sold into high street retailers and independent beauty shops across the UK, Europe, Australia and the US. In 2016, W7 was supplied to over 250 customers in more than 50 countries.

In 2017 Warpaint completed the acquisition of Retra Holdings Limited, a UK colour cosmetics business with a significant focus on the gifting market, principally for high street retailers and supermarkets including Boots, Superdrug and Asda. Retra owns three major brands: Technic, Body Collection and Man's Stuff, in addition to supplying white label cosmetics produced for several major high street retailers including Asda and Matalan.

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

NRAPGUCPCUPRGQW

Close

×

RNS Number : 4410L

Avanti Communications Group Plc

19 April 2018

 

 

19 April 2018

 

Avanti Communications announces its HYLAS 4 satellite has successfully reached its geostationary orbital position

 

Avanti Communications Group PLC (AIM: AVN), ("Avanti", the "Company") announces that following its successful launch on 5th April 2018, the HYLAS 4 Ka-band satellite has reached its geostationary orbital position on schedule.

The spacecraft is performing as expected and is in good health. The solar arrays, antenna pallets and electric propulsion thrusters have been successfully deployed. The in-orbit payload testing will begin shortly with service commencing as scheduled at the end of July

For further information, please contact:

Avanti Communications	Nigel Fox, Patrick Willcocks Tel: +44 20 7749 1600
Montfort	Nick Miles,  James Olley Tel: +44 203 770 7909
Cenkos Securities (Nomad)	Max Hartley, Nicholas Wells, Harry Hargreaves Tel: +44 207 397 8900
Redleaf Communications	Ralph Anderson +44 (0)20 3757 6883

 

 

 

 

 

 

Notes to Editors:

About Avanti Communications

Avanti connects people wherever they are – in their homes, businesses, in government and on mobiles. Through the HYLAS satellite fleet and partners in 118 countries, the network provides ubiquitous internet service to a quarter of the world's population. Avanti delivers the level of quality and flexibility that the most demanding telecoms customers in the world seek.

 

Avanti is the first mover in high throughput satellite data communications in EMEA. It has rights to orbital slots and Ka-band spectrum in perpetuity that covers an end market of over 1.7bn people.

 

The Group has invested $1.2bn in a network that incorporates satellites, ground stations, datacentres and a fibre ring.

 

Avanti has a unique Cloud based customer interface that is protected by patented technology.

 

Avanti Communications is listed in London on AIM (AVN:LSE).

www.avantiplc.com 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

MSCLIFFDSEIALIT

Close

×

RNS Number : 2328L

N4 Pharma PLC

18 April 2018

 

N4 Pharma Plc

("N4 Pharma" or the "Company")

Commencement of Sildenafil Clinical Trial

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company which improves the delivery of existing drugs and novel vaccines and therapeutics, is pleased to announce the start of its proof of concept clinical trial for its lead product, sildenafil, (the "Trial") following the completion of the validation of the reformulated sildenafil in accordance with the specifications submitted to the MHRA.

 

The Trial will comprise a four way crossover study in 12 healthy subjects comparing N4 Pharma's reformulated 100mg sildenafil to Viagra™ 50mg in both fed and fasted conditions. The Trial aims to measure the level of the drug in plasma achieved by N4 Pharma's reformulated product compared to Viagra™ over a 24 hour period.

 

The Trial is expected to take 8 to 10 weeks with provisional results data available in July 2018 with the final clinical study report expected at the end of August 2018.

 

The data gathered from the Trial will enable the Company to establish whether its reformulation has been sufficiently successful to allow N4 Pharma to prepare for a pre-IND meeting with the FDA towards the end of this year or whether further amendments to the reformulation may be required to optimise efficacy.

 

Nigel Theobald, CEO of N4 Pharma, commented: "We are delighted that N4 Pharma's first clinical trial has begun on our lead product, sildenafil. Slight delays in receiving the base ingredients to the reformulation, which had a knock effect on the validation of the product, has seen the timetable slip slightly. However, there should be no material impact on any move towards commercialisation assuming successful Trial results.

 

"The Board continues to believe that the improvements sought to be evidenced through the Trial will make our reformulation that much more attractive to both the end consumer and pharmaceutical partners in the final development and commercialisation of the drug in this highly lucrative market.

 

"We look forward to providing a further update as soon as we receive the full results which are expected in late August."

 

Enquiries:

 

N4 Pharma Plc Nigel Theobald, CEO	Via Alma PR
Stockdale Securities Tom Griffiths	Tel: +44(0)20 7601 6100
Alma PR Josh Royston Robyn Fisher	Tel: +44(0)778 090 1979 Tel: +44(0)754 070 6191

 

 

 

 

About N4 Pharma

 

N4 Pharma is a specialist pharmaceutical company which reformulates existing drugs and vaccines to improve their performance.

N4 Pharma's reformulation work falls under two divisions:

• generic, already commercialised, drugs; and

• delivery of novel and existing vaccines and therapeutics.

N4 Pharma has identified a number of established drugs that could be improved upon through its reformulation techniques. N4 Pharma's most advanced reformulation is for sildenafil, widely marketed as Viagra™, where N4 Pharma is seeking to improve the speed at which the drug takes effect whilst also extending its duration of action.

N4 Pharma's reformulation approach should take approximately three years to obtain regulatory approval as opposed to the traditional process for new drugs of on average ten years. The cost and risk profile of this model is also significantly less than the traditional process. N4 Pharma's business model for generics is to take reformulated drugs from its portfolio through to the stage where it will license its newly reformulated drugs to pharmaceutical companies to commercialise them. N4 Pharma's revenues should be derived from up front milestone and royalty payments associated with the licence.

N4 Pharma's business model for vaccines is to undertake the required clinical work to demonstrate the capability of its delivery system as a cancer vaccine or therapeutic treatment so that it can license the technology to major players developing treatments in this area, again in return for up front milestone and royalty payments associated with the licence.

Sildenafil Market Research:  

 

·     Market research undertaken by Black Swan Analysis in 2017 with clinicians in the UK and US who are currently prescribing sildenafil and competing products Vardenafil and Tadalafil which suggested that between 12% and 25% of clinicians in the UK (depending on the product) would switch patients to N4 Pharma's product and between 19% and 28% of clinicians in the US would do the same.

·     The size of the addressable market for sildenafil: the erectile dysfunction market had global annual sales of approximately $4.6 billion* in 2016 and is expected to fall to $3.2 billion by 2022 due to the anticipated patent expiry of Viagra™ and Cialis.

 

*Source: Evaluate Pharma

 

 

Glossary:

 

"MHRA"	The Medicines and Healthcare products Regulatory Agency
"Pre-IND"	Pre-Investigational New Product
"FDA"	Food and Drug Administration

 

 

 

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

MSCLLFIRSRIDLIT

Close

×

RNS Number : 9426K

Solid State PLC

16 April 2018

 

 

Solid State plc

("Solid State", the "Group" or the "Company")

 

New Power Solutions distribution franchise won

 

Solid State plc (AIM: SOLI), the AIM listed manufacturer of computing, power and communications products, and value added distributor of electronic components, is pleased to announce a distribution franchise for VPT, a leading global provider of power conversion solutions for the rapid deployment of critical power systems in avionics, military and space applications.

 

Solid State Supplies has been chosen by VPT due to its extensive military and aerospace knowledge, its certification to AS9120, its existing industry client base and value added distribution capabilities.   The franchise is for exclusive rights to UK and Ireland and includes the transfer of the existing client base.

 

VPT has been selling into the UK market for 18 years to a loyal client base.  Its products do not overlap with the current Solid State Supplies range giving the opportunity to develop and expand the client's reach and product representation into relevant markets.

John Macmichael, Managing Director of Solid State Supplies, commented:

"The VPT product range complements the existing Solid State power operations.  They are an innovative, high quality supplier where we are confident that our approach will increase sales beyond the current run rate and broaden the customer base." 

 

For further information please contact:

 

Solid State plc	01527 830 630
Gary Marsh – Chief Executive Peter James – Group Finance Director	[email protected]
WH Ireland (Nominated Adviser & Joint Broker)	0117 945 3470
Mike Coe / Ed Allsopp (Corporate Finance) Jasper Berry / David Kilbourn (Corporate Broking / Sales)
finnCap (Joint Broker) Ed Frisby / Kate Bannatyne (Corporate Finance) Emily Morris / Rhys Williams (Corporate Broking / Sales)	020 7220 0500
Walbrook PR (Financial PR)	020 7933 8780
Tom Cooper / Paul Vann	0797 122 1972
	[email protected]

 

 

Notes to Editors:

 

Solid State plc (SOLI) is a leading value added group of companies providing specialist design-in and manufacturing services to those acquiring computing, power and communications products and electronic component services for use in harsh environments. 

 

Serving niche markets in oil & gas production, medical, construction, security, military and field maintenance, Solid State acts as both a component supplier to OEMs and bespoke manufacturer of specialist units to clients with complex requirements.

 

Headquartered in Redditch, Solid State employs over 200 staff across five sites.  Solid State operates through two main divisions: Solid State Supplies and Steatite.

 

Solid State was established in 1971 and admitted to AIM in June 1996.

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

NRAUOABRWRASAAR

Close